Naperiglipron - Eli Lilly
Alternative Names: GLP-1R NPA II - Eli Lilly; LY-3549492Latest Information Update: 10 Oct 2025
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 14 Aug 2025 Eli Lily and Company terminates a phase II trial in healthy volunteers in Canada and USA (PO) for strategic business reasons (NCT07085468)
- 29 Jul 2025 Eli Lily terminates a phase II trial in Obesity and Type 2 diabetes mellitus in Argentina, USA (PO) due to strategic business reasons (NCT07030868)
- 25 Jul 2025 Eli Lilly and Company plans a phase II trial in Obesity (In volunteers) in USA and Canada (PO) in August 2025 (NCT07085468)